The relationship between arterial hypertension and long COVID
Abstract
Background. Рost-COVID-19 syndrome (long COVID) is the signs and symptoms that develop during or after COVID-19 infection that last for more than 12 weeks and are not explained by an alternative diagnosis.
Purpose. To identify the features of the course of long COVID in patients with arterial hypertension.
Materials and methods. A study was conducted with 104 patients (mean age 49.5±6.4 years) hospitalized due to viral pneumonia caused by COVID-19. Group 1 included 49 patients with arterial hypertension (AH) (47.1%), group 2 – 55 patients without AH (52.9%). The patient's condition was assessed during hospitalization, before discharge, 1-2 days after discharge, and then remotely after 3, 6, and 12 months. In addition to routine methods, the prevalence of various symptoms characteristic of long COVID was studied. The assessment of well-being was carried out on a 10–point scale, where 1 point – "very bad", 10 points - "excellent".
The statistical analysis was performed using the StatTech v program. 4.6.3 (developed by Stattech LLC, Russia).
Results. The presence of hypertension negatively affects the course of long COVID in the form of a deterioration in general well-being compared to the state before coronavirus infection. In group 1, the well-being index at the first visit after discharge from the hospital was lower than in group 2 (7 [6.98;7.03] and 8 [7.96;8.01], respectively, p=0.008). The absence of hypertension had a positive effect on the dynamics of myalgia and glucose levels in the postcovoid period (p<0.05).
Conclusion. Thus, the presence of hypertension in patients with coronavirus infection complicated by pneumonia entails the persistence of postcovoid symptoms. Therefore, they need regular dynamic monitoring for at least a year after suffering from COVID-19.
EDN: UZIPRB
Downloads
References
Liu, F., Long, X., Zhang, B., Zhang, W., Chen, X., & Zhang, Z. (2020). ACE2 expression in pancreas may cause pancreatic damage after SARS CoV 2 infection. Clinical Gastroenterology and Hepatology, 18(2), 2128–2130. https://doi.org/10.1016/j.cgh.2020.04.040. EDN: https://elibrary.ru/WFHOON
Yang, G., Tan, Z., Zhou, L., Yang, M., Peng, L., Liu, J., Cai, J., Yang, R., Han, J., Huang, Y., & He, S. (2020). Angiotensin II receptor blockers and angiotensin converting enzyme inhibitors usage is associated with improved inflammatory status and clinical outcomes in COVID 19 patients with hypertension. MedRxiv. https://doi.org/10.1101/2020.03.31.20038935
Baral, R., Tsampasian, V., Debski, M., Moran, B., Garg, P., Clark, A., & Vassiliou, V. S. (2021). Association between renin angiotensin aldosterone system inhibitors and clinical outcomes in patients with COVID 19: a systematic review and meta analysis. JAMA Network Open, 4(3), e213594. https://doi.org/10.1001/jamanetworkopen.2021.3594. EDN: https://elibrary.ru/HDOWFM
Mehra, M. R., Desai, S. S., Kuy, S., Henry, T. D., & Patel, A. N. (2020). Cardiovascular disease, drug therapy, and mortality in COVID 19. The New England Journal of Medicine, 382(25), e102. https://doi.org/10.1056/NEJMoa2007621. EDN: https://elibrary.ru/ZPIIJZ
Carod Artal, F. J. (2021). Post COVID 19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Revista de Neurologia, 72(11), 384–396. https://doi.org/10.33588/RN.7211.2021230. EDN: https://elibrary.ru/ARZZGT
Santos, A., Magro, D. O., Evangelista Poderoso, R., & Saad, M. J. A. (2021). Diabetes, obesity, and insulin resistance in COVID 19: molecular interrelationship and therapeutic implications. Diabetology and Metabolic Syndrome, 13(1), 23. https://doi.org/10.1186/s13098-021-00639-2. EDN: https://elibrary.ru/DHEUAO
Hasan, L. K., Deadwiler, B., Haratian, A., Bolia, I. K., Weber, A. E., & Petrigliano, F. A. (2021). Effects of COVID 19 on the musculoskeletal system: clinician’s guide. Orthopedic Research and Reviews, 13, 141–150. https://doi.org/10.2147/ORR.S321884. EDN: https://elibrary.ru/EJLMZO
Klingenstein, M., Klingenstein, S., Neckel, P. H., Mack, A. F., Wagner, A. P., Kleger, A., Liebau, S., & Milazzo, A. (2021). Evidence of SARS CoV2 entry protein ACE2 in the human nose and olfactory bulb. Cells Tissues Organs, 209, 155–164. https://doi.org/10.1159/000513040. EDN: https://elibrary.ru/WMZZSP
Gupta, A., Madhavan, M. V., Sehgal, K., Nair, N., Mahajan, S., Sehrawat, T. S., Bikdeli, B., Ahluwalia, N., Ausiello, J. C., Wan, E. Y., Freedberg, D. E., Kirtane, A. J., Parikh, S. A., Maurer, M. S., Nordvig, A. S., Accili, D., Bathon, J. M., Mohan, S., Bauer, K. A., Leon, M. B., Krumholz, H. M., Uriel, N., Mehra, M. R., Elkind, M. S. V., Stone, G. W., Schwartz, A., Ho, D. D., Bilezikian, J. P., & Landry, D. W. (2020). Extrapulmonary manifestations of COVID 19. Nature Medicine, 26(7), 1017–1032. https://doi.org/10.1038/s41591-020-0968-3. EDN: https://elibrary.ru/HTAOKQ
Li, X. C., Zhang, J., & Zhuo, J. L. (2017). The vasoprotective axes of the renin angiotensin system: physiological relevance and therapeutic implications in cardiovascular, hypertensive and kidney diseases. Pharmacological Research, 125, 21–38. https://doi.org/10.1016/j.phrs.2017.06.005. EDN: https://elibrary.ru/YFYWLE
Chaudhry, F., Lavandero, S., Xie, X., Sabharwal, B., Zheng, Y. Y., Correa, A., Narula, J., & Levy, P. (2020). Manipulation of ACE 2 expression in COVID 19. Open Heart, 7(2), e001424. https://doi.org/10.1136/openhrt-2020-001424. EDN: https://elibrary.ru/GPUUQL
Brann, D. H., Tsukahara, T., Weinreb, C., Lipovsek, M., Van den Berge, K., Gong, B., Chance, R., Macaulay, I. C., Chou, H. J., Fletcher, R. B., Das, D., Street, K., de Bezieux, H. R., Choi, Y. G., Risso, D., Dudoit, S., Purdom, E., Mill, J., Hachem, R. A., Matsunami, H., Logan, D. W., Goldstein, B. J., Grubb, M. S., Ngai, J., & Datta, S. R. (2020). Non neuronal expression of SARS CoV 2 entry genes in the olfactory system suggests mechanisms underlying COVID 19 associated anosmia. Science Advances, 6(31), eabc5801. https://doi.org/10.1126/sciadv.abc5801. EDN: https://elibrary.ru/XIHMPQ
Schepens, E. J. A., Boek, W. M., Boesveldt, S., Stokroos, R. J., Stegeman, I., & Kamalski, D. M. A. (2023). One year psychophysical evaluation of COVID 19 induced olfactory disorders: a prospective cohort study. BMC Medicine, 21(1), 490. https://doi.org/10.1186/s12916-023-03205-x. EDN: https://elibrary.ru/YDOBDG
Pavli, A., Theodoridou, M., & Maltezou, H. C. (2021). Post COVID syndrome: incidence, clinical spectrum, and challenges for primary healthcare professionals. Archives of Medical Research, 52(6), 575–581. https://doi.org/10.1016/j.arcmed.2021.03.010. EDN: https://elibrary.ru/DSLLRT
Fernández de Las Peñas, C., Torres Macho, J., Velasco Arribas, M., Plaza Canteli, S., Arias Navalón, J. A., Hernández Barrera, V., & Guijarro, C. (2022). Preexisting hypertension is associated with a greater number of long term post COVID symptoms and poor sleep quality: a case control study. Journal of Human Hypertension, 36(6), 582–584. https://doi.org/10.1038/s41371-022-00660-6. EDN: https://elibrary.ru/WSBNDI
Meng, J., Xiao, G., Zhang, J., He, X., Ou, M., Bi, J., Yang, R., Di, W., Wang, Z., Li, Z., Gao, H., Liu, L., & Zhang, G. (2020). Renin angiotensin system inhibitors improve the clinical outcomes of COVID 19 patients with hypertension. Emerging Microbes & Infections, 9(1), 757–760. https://doi.org/10.1080/22221751.2020.1746200. EDN: https://elibrary.ru/ISONOJ
Moein, S. T., Hashemian, S. M., Mansourafshar, B., Khorram Tousi, A., Tabarsi, P., & Doty, R. L. (2020). Smell dysfunction: a biomarker for COVID 19. International Forum of Allergy and Rhinology, 10(8), 944–950. https://doi.org/10.1002/alr.22587. EDN: https://elibrary.ru/JWQHKV
Zhu, H., Zhang, L., Ma, Y., Zhai, M., Xia, L., Liu, J., Yu, S., & Duan, W. (2021). The role of SARS CoV 2 target ACE2 in cardiovascular diseases. Journal of Cellular and Molecular Medicine, 25(3), 1342–1349. https://doi.org/10.1111/jcmm.16239. EDN: https://elibrary.ru/NCGSHO
Xiao, L., Sakagami, H., & Miwa, N. (2020). ACE2: The key molecule for understanding the pathophysiology of severe and critical conditions of COVID 19: Demon or angel? Viruses, 12(5), 491. https://doi.org/10.3390/v12050491. EDN: https://elibrary.ru/TJBPIM
Zhang, X., Li, S., & Niu, S. (2020). ACE2 and COVID 19 and the resulting ARDS. Postgraduate Medical Journal, 96(1137), 403–407. https://doi.org/10.1136/postgradmedj-2020-137935. EDN: https://elibrary.ru/BTLKOK
Copyright (c) 2025 Liutsiia I. Feiskhanova, Ekaterina E. Petrova, Zulfiya F. Kim, Stanislav Yu. Scherbakov
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
